What is Keytruda (Keytruda®)?

Keytruda, pembrolizumabis a prescription medicine, an innovative breakthrough drug, humanized monoclonal antibody.

Keytruda belongs to the “immunotherapy” drugs that help the immune system attack the tumor. This contrasts, for example, with chemotherapy that directly affects tumor cells.

Keytruda and immunotherapy is therapeutic strategy has revolutionized the treatment of cancer in recent years and is one of the most studied strategies in the world for many types of cancer and different stages of treatments.

What is Keytruda used for?

Keytruda is prescribed by an oncologist and is used to treat various types of cancer, for example:

Advanced melanoma skin cancer when the disease has spread or cannot be removed by surgery.

Advanced non small cell lung cancer, NSCLC, for patients with positive for PDL1 and not received chemotherapy and the tumor express EGFR or ALK gene/mutation.

Other cases can be for patients who received platinum chemotherapy and it is no longer working and the patients tumor express EGFR or ALK gene/mutation.

Other cases can be patients that also received an EGFR or ALK inhibitor medicine and it did not work any more.

Advanced head and neck squamous cells cancer, HNSCC. if the disease has returned or spread and previous platinum chemotherapy  is no longer working.

Hodgkin lymphoma, cHL, in adults and children if the disease has returned and if the patients received 3 or more types of treatment.

Bladder and urinary tract cancer, urothelial carcinoma – for  metastatic disease or patients who can not receive cisplatin, or cases of a disease that progresses during chemotherapy treatment.

Cancer types among adults and children that is shown by a laboratory test to be a microsatellite instability high (MSI-H), or a mismatch repair deficient (dMMR) solid tumor.

Here there are a few points to consider, for example the cancer has spread or cannot be removed by surgery and there are no other satisfactory treatment options, or advanced colorectal cancer although a chemotherapy treatment

Advanced stomach cancer or gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma that tests positive for PDL1  if  chemotherapy did not work and the tumor has an abnormal HER2/neu gene/mutation, and the patient received a HER2/neu-targeted medicine.

What is it important to notice?

Ask your Oncologist how to use Keytruda if you are not sure.

The dosage and duration of Keytruda treatment will be determined by the doctor only.

Read the Patient leaflet guide which is enclosed to each package.

Keytruda side effects-

We wish you full health!

All rights reserved to Merck Sharp & Dohme Corp., New-Jersey, USA.

To Read More>>

Read our publications on innovative treatments for cancer:

To check if our service suits your case
We need to talk

Improve therapeutic outcomes, prolong life and quality of life, is our main business.
We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.

Article categories

קטגוריות המאמרים

Popular topics


Bladder Cancer – Padcev Plus Keytruda in 1st Line


Cisplatin-based combination chemotherapy remains the standard of care for locally advanced or metastatic bladder cancer.

However, toxicity is substantial, responses are rarely durable, and many locally advanced or metastatic patients are ineligible.

Padcev and Keytruda have each shown a survival benefit versus chemotherapy in Bladder Cancer, are not restricted by cisplatin eligibility, and warrant investigation as a first-line combination therapy in patients ineligible for cisplatin.


Padcev, also called Enfortumab Vedotin, is an antibody-drug conjugate used for the treatment of bladder cancer.

The most common side effects include fatigue, peripheral neuropathy, decreased appetite, rash, alopecia (hair loss), nausea, altered taste, diarrhea, dry eye, pruritus (itching) and dry skin.

The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.


Keytruda, also called Pembrolizumab, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer.

Common side effects include fatigue, musculoskeletal pain, decreased appetite, itchy skin (pruritus), diarrhea, nausea, rash, fever (pyrexia), cough, difficulty breathing (dyspnea), constipation, pain, and abdominal pain.

It is a type of antibody that blocks a protective mechanism of cancer cells and thereby, allows the immune system to destroy them.

It targets the PD-1 receptor of lymphocytes.

Keytruda was approved for medical use in the United States in 2014. In 2017, the US Food and Drug Administration (FDA) approved it for any unresectable or metastatic solid tumor with certain genetic anomalies.

It is on the World Health Organization’s List of Essential Medicines.


In this Phase 1b/2 study, first-line cisplatin-ineligible locally advanced or metastatic patients received Padcev 1.25 mg/kg (Days 1 and 8) and Keytruda 200 mg (Day 1) intravenously in 3-week cycles.


Forty-five patients received Padcev plus Keytruda. The most common treatment-related side effects were peripheral sensory neuropathy, fatigue and alopecia.

Twenty-nine patients had difficult side effects. The most common were increased lipase, maculopapular rash and fatigue.

One death was associated with the treatment.

73.3% of patient benefited from the treatment experiencing a decrease in lesions’ size. In these patients the median Survival was 25.6 months.

15.6% of patients had complete remission. In these patients the median Survival was 26.1 months.


Padcev plus Keytruda showed a manageable safety profile.

Most patients experienced tumor shrinkage.

The median Survival exceeded 2 years in a cisplatin-ineligible patient population make this a promising combination.

Talk to us so see if we can help you to actually get the most advanced treatments


Because we, do not give up on life!

Contact us 24/7 –

Call center +44.2082.426.039

Read more about bladder cancer >>

Bladder Cancer - Padcev Plus Keytruda in 1st Line
Bladder Cancer – Padcev Plus Keytruda in 1st Line

No Cost service compatibility check
Please fill in the details and we will back to you as soon as possible

Improving therapeutic success, extending life and quality of life are our main business. We extend to metastatic cancer patients and patients with brain tumors, the most advanced treatment options in the world and the best experts in Israel and abroad.

Article categories

קטגוריות המאמרים

Popular topics